We are live on ! Find out more
SLN

Silence Therapeutics
SLN

71 hedge funds and large institutions have $502M invested in Silence Therapeutics in 2024 Q2 according to their latest regulatory filings, with 12 funds opening new positions, 22 increasing their positions, 19 reducing their positions, and 5 closing their positions.

New
Increased
Maintained
Reduced
Closed

140% more first-time investments, than exits

New positions opened: 12 | Existing positions closed: 5

16% more repeat investments, than reductions

Existing positions increased: 22 | Existing positions reduced: 19

11% more funds holding

Funds holding: 64 → 71 (+7)

0.42% less ownership

Funds ownership: 19.87% → 19.45% (-0.42%)

15% less capital invested

Capital invested by funds: $588M → $502M (-$85.9M)

25% less funds holding in top 10

Funds holding in top 10: 8 → 6 (-2)

Holders
71
Holders Change
+7
Holders Change %
+10.94%
% of All Funds
1.03%
Holding in Top 10
6
Holding in Top 10 Change
-2
Holding in Top 10 Change %
-25%
% of All Funds
0.09%
New
12
Increased
22
Reduced
19
Closed
5
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
FTM
First Turn Management
California
+$11.4M
2
IC
Ikarian Capital
Texas
+$10.8M
3
PCH
Polar Capital Holdings
United Kingdom
+$9.36M
4
Millennium Management
Millennium Management
New York
+$7.94M
5
SG Americas Securities
SG Americas Securities
New York
+$7.15M

Top Sellers

Rank Fund Capital Flow
1
LOAME
Lombard Odier Asset Management (Europe)
United Kingdom
-$48.3M
2
LCM
Lynx1 Capital Management
Puerto Rico
-$11.4M
3
DTC
Deep Track Capital
Connecticut
-$6.04M
4
WP
Woodline Partners
California
-$3.14M
5
OCA
Octagon Capital Advisors
New York
-$2.96M
Name Holding Trade Value Shares
Change 		Change in
Stake
MCM
26
M28 Capital Management
Connecticut
$3.52M -$2.43M -114,300 -38%
HSBC Holdings
27
HSBC Holdings
United Kingdom
$3.41M – – –
OCA
28
Octagon Capital Advisors
New York
$3.34M -$2.96M -139,000 -44%
IC
29
Ikarian Capital
Texas
$3.29M +$10.8M +506,665 New
NIP
30
Nicholas Investment Partners
California
$2.86M +$3.2M +150,480 New
Marshall Wace
31
Marshall Wace
United Kingdom
$2.84M +$217K +10,206 +7%
BFM
32
Boothbay Fund Management
New York
$2.79M +$417K +19,628 +15%
Point72 Asset Management
33
Point72 Asset Management
Connecticut
$2.78M +$2.94M +138,300 +1,687%
SC
34
Stempoint Capital
New York
$2.37M +$2.66M +124,866 New
Citadel Advisors
35
Citadel Advisors
Florida
$2.22M +$1.58M +74,078 +174%
BC
36
BIT Capital
Germany
$1.92M +$260K +12,235 +14%
Two Sigma Investments
37
Two Sigma Investments
New York
$1.88M -$172K -8,105 -8%
WP
38
Woodline Partners
California
$1.73M -$3.14M -147,518 -62%
UOC
39
UBS O'Connor
Illinois
$1.46M +$98.2K +4,617 +6%
Two Sigma Advisers
40
Two Sigma Advisers
New York
$1.45M -$25.5K -1,200 -2%
SSA
41
Schonfeld Strategic Advisors
New York
$1.43M -$1.23M -57,963 -44%
Walleye Capital
42
Walleye Capital
New York
$1.41M -$374K -17,599 -19%
UBS Group
43
UBS Group
Switzerland
$1.4M +$40.1K +1,888 +3%
Citigroup
44
Citigroup
New York
$1.11M – – –
AGP
45
Artia Global Partners
Florida
$997K – – –
ACM
46
ADAR1 Capital Management
Texas
$766K +$4.25K +200 +0.5%
Renaissance Technologies
47
Renaissance Technologies
New York
$743K -$1.38M -64,800 -62%
NIM
48
NEOS Investment Management
Connecticut
$706K +$542K +25,508 +219%
Geode Capital Management
49
Geode Capital Management
Massachusetts
$559K +$149K +6,990 +31%
William Blair & Company
50
William Blair & Company
Illinois
$483K – – –
1
2
3 4

SLN Hedge Fund Activity: Q2 2024 in Review

71 of the 6,924 institutional investors tracked by Wall St. Rank reported a position in Silence Therapeutics (SLN) for Q2 2024, worth a combined $502M — down 15% from $588M a quarter earlier.

Buyers outnumbered sellers: 12 funds opened new SLN positions and 5 closed out — a net gain of 7 holders — while 22 added to existing stakes and 19 trimmed.

The largest buyer was First Turn Management, opening a new position worth an estimated $11.4M. The largest seller was Lombard Odier Asset Management (Europe), exiting entirely with an estimated $48.3M sold.

  • 71 institutional investors held Silence Therapeutics (SLN) as of Q2 2024, up from 64 in Q1 2024.
  • Funds reported $502M of Silence Therapeutics stock for Q2 2024, down 15% quarter-over-quarter.
  • 12 funds opened new Silence Therapeutics positions in Q2 2024 and 5 closed out, a net change of +7 holders.
  • The largest Silence Therapeutics buyer in Q2 2024 was First Turn Management, an estimated $11.4M added.
  • The largest Silence Therapeutics seller in Q2 2024 was Lombard Odier Asset Management (Europe), an estimated $48.3M sold.

Based on aggregated 13F filings for Q2 2024.